X
[{"orgOrder":0,"company":"Spiral Therapeutics","sponsor":"Savoir Capital","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Meniere's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Spiral Therapeutics
Filters
×
FILTER:
Company
Sponsor
Country
Therapeutic Area
Study Phase
Companies By Therapeutic Area
Details:
SPT-2101 is a sustained-release steroid formulation designed for precise inner ear administration using Spiral's novel delivery procedure. Spiral recently completed enrollment of an open label pilot clinical study of SPT-2101 in 10 patients with Meniere's disease.
Lead Product(s):
SPT-2101
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SPT-2101
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Savoir Capital
Deal Size: $8.2 million
Upfront Cash: Undisclosed
Deal Type: Financing
January 10, 2023